Sino Biopharmaceutical (HK:1177) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Sino Biopharmaceutical has received approval from China’s National Medical Products Administration for its Benmelstobart Injection, in combination with Anlotinib Hydrochloride Capsule, to treat recurrent or metastatic endometrial cancer. This marks the second approval for Benmelstobart and the seventh for Anlotinib, highlighting significant potential in addressing unmet needs for patients with limited treatment options. The company’s commitment to advancing innovative therapies continues with ongoing Phase III trials for various cancers.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
